Retinal Imaging

Is retinal vasculature a biomarker in amyloid proven Alzheimer’s disease?

Jurre den Haan\textsuperscript{a,}\textsuperscript{*}, Jacoba A. van de Kreeke\textsuperscript{b}, Bart N. van Berckel\textsuperscript{c}, Frederik Barkhof\textsuperscript{c,d}, Charlotte E. Teunissen\textsuperscript{e}, Philip Scheltens\textsuperscript{a}, Frank D. Verbraak\textsuperscript{b}, Femke H. Bouwman\textsuperscript{a}

\textsuperscript{a}Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands
\textsuperscript{b}Department of Ophthalmology, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands
\textsuperscript{c}Department of Radiology and Nuclear Medicine, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands
\textsuperscript{d}UCL institutes of Neurology and Healthcare Engineering, London, UK
\textsuperscript{e}Neurochemistry Lab and Biobank, Department of Clinical Chemistry, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands

Abstract

Introduction: The retina is a potential source of noninvasive vascular biomarkers for Alzheimer’s disease (AD). We assessed retinal microvasculature in well-characterized AD cases, taking ophthalmological confounders into account.

Methods: We included 48 amyloid-positive AD patients and 38 amyloid-negative cognitively normal control subjects. All participants underwent ophthalmological screening to exclude interfering ocular disease. Using a multimodal approach, we measured retinal vascular parameters, choroidal thickness, macular vascular density, and foveal avascular zone size.

Results: We found no disease effects on retinal vascular measures (all $\beta$'s $< 0.15$, all $P > .2$), adjusted for confounders. Venular tortuosity was inversely associated with Fazekas score in control subjects ($\beta = -0.56$, $P < .01$), while vessel density in the outer ring of the macula was inversely associated with Fazekas score in AD cases ($\beta = -0.64$, $P < .01$).

Discussion: In conclusion, retinal vasculature did not discriminate patients with AD from control subjects, despite evident changes on clinical, neuroimaging, and cerebrospinal fluid biomarkers, challenging the use of retinal vasculature measurements as AD biomarker.

Keywords: Retinal vasculature; Alzheimer’s disease; Biomarker; Choroidal thickness; OCTA; Fundus photographs

1. Background

Alzheimer’s disease (AD) pathophysiology is characterized by amyloid beta (A\textsubscript{\textbeta}) accumulation, tau hyperphosphorylation, and neurodegeneration, ultimately leading to cognitive decline \[1\]. In addition, vascular changes are involved in AD pathophysiology. Vascular changes, either intrinsic or as copathology, interact with AD pathology, neurodegeneration, and cognitive impairment \[2,3\] and are described with the term vascular cognitive impairment (VCI) \[4,5\]. Vascular pathology is prevalent and described at autopsy in up to 75% of dementia cases \[4,6\]. Vascular changes include white matter hyperintensities (WMHs) as a result of chronic (subcortical) ischemia of small vessels, large vessel infarcts, lacunar infarcts (e.g. thalamus), arteriosclerosis and atherosclerosis, and cerebral amyloid angiopathy (CAA) \[7,8\]. CAA is an intravascular pathology in which A\textsubscript{\textbeta} is deposited in the vessel wall and is associated with microhemorrhages and microinfarcts \[9\]. Its prevalence is...
between 20% and 40% in nondemented elderly and 50-60% in demented elderly in autopsy studies [9,10]. A strong correlation between AD and CAA exists, as in postmortem AD brains, in 85-95% of the cases CAA is found [9]. Moreover, recent studies also showed that decreased cerebral blood flow and blood-brain barrier alterations might be involved in AD pathophysiology, possibly playing a role in Aβ clearance [2,3]. Currently used biomarkers for vascular changes are limited to magnetic resonance imaging (MRI) [8]. To better understand and measure vascular changes in AD, new biomarkers for vascular changes might increase pathophysiological insight and could complement the currently used ATN system for amyloid(A), tau(T), and neurodegeneration(N) [11].

The retina is a possible source of vascular biomarkers as retinal vasculature can be imaged noninvasively at the micrometer level using different imaging modalities, including fundus photography, measurements of choroidal thickness (using enhanced depth imaging optical coherence tomography (EDI-OCT) and OCT angiography (OCTA). Vascular changes in the retina have been described in AD, including changes in vascular parameters from fundus photography analysis, using Singapore I Vessel analysis (SIVA) software, such as increased venous diameter, decreased arterial diameter, and decreased fractional dimension [12]. In contrast, a recent report showed an absence of group differences between AD patients and control participants, while showing decreased total and arteriolar fractal dimensions in VCI cases [13]. In addition, choroidal thinning in AD is reported in several studies using EDI-OCT [14–17]. Recent reports on retinal vasculature with OCTA reported increased foveal avascular zone (FAZ) size and decreased vessel density and flow in AD [18,19] and preclinical AD [20].

As ophthalmological comorbidity could potentially influence retinal vascular measurements and is often asymptomatic, a thorough ophthalmological screening is warranted. Second, assessing retinal biomarkers in patients with a confirmed AD diagnosis by established biomarkers such as cortical atrophy, amyloid and tau in cerebrospinal fluid (CSF) or amyloid positron emission tomography (PET) supports the clinical diagnosis on one hand and allows comparison of the new biomarkers to the gold standard on the other hand.

The aim of this study was to identify retinal vascular biomarkers as possible noninvasive biomarkers in AD. Following previous publications, we hypothesize to find increased central retinal artery equivalent (CRAE), decreased central retinal vein equivalent (CRVE), decreased fractal dimension, thinner choroidal thickness, smaller vessel density, and larger FAZ in AD compared to control cases. We, therefore, measured retinal vascular parameters using fundus photography, EDI-OCT, and OCTA in well-characterized amyloid-positive AD cases, while taking ophthalmological confounders into account. In addition, we assessed relationships between retinal vascular parameters and WMHs on MRI.

2. Methods

2.1. Subjects

We assessed 50 AD patients and 38 control subjects from the Amsterdam Dementia Cohort (ADC) that were enrolled into our retinal imaging cohort as described earlier (all Mini-Mental State Examination (MMSE) ≥17, capable of giving informed consent) [21]. In brief, all patients and control subjects underwent a standardized screening protocol including (medical) history, neuropsychological examination, blood draw for apolipoprotein E ε4/ε4 (APOE ε4/ε4) genotype, blood pressure measurements, neuroimaging, and lumbar puncture [22]. All patients met National Institute on Aging and Alzheimer’s Association criteria of AD and had evidence of amyloid pathology based on CSF analysis or amyloid PET [11]. Controls were subjects with cognitive complaints that showed no evidence of objective cognitive impairment, neurodegeneration, or amyloid pathology based on amyloid PET or CSF analysis.

2.2. MRI scanning

MRI scans were reviewed by an experienced and blinded rater (FB) before the multidisciplinary meeting of the ADC, where a clinical diagnosis was made by consensus. Visual rating scores for atrophy on MRI were determined based on T1-weighted images and included medial temporal lobe atrophy, global cortical atrophy, and parietal cortical atrophy [23–25]. Vascular assessment included Fazekas score for white matter hyperintensities (fluid attenuation inversion recovery sequence), assessment of lacunar infarcts (fluid attenuation inversion recovery, T2-weighted sequences), and microbleeds (T2*-sequence) [26].

2.3. Cerebrospinal fluid analysis

CSF was analyzed using Innotest ELISA and measured amyloid-beta-1-42(AB1-42), tau181, and phosphorylated Tau (pTau). A tau181/AB1-42 ratio ≥.52 was considered an AD profile [27].

2.4. Amyloid PET analysis

A subset of cases was enrolled in research programs that included amyloid PET scanning with the following tracers: 18F-Florbetaben (NeuraCeq) (n = 24), 18F-Florbetapir (Amyvid) (n = 9), and Pittsburgh compound ((11C-PIB) (n = 3). Parametric standardized uptake value images of amyloid PET scans were assessed by an experienced rater (BvB) and visually interpreted as amyloid positive or amyloid negative following guidelines for individual tracers.
2.5. Ophthalmological assessment

Subjects were included within a year after the ADC diagnostic screening program and underwent the following eye examinations to exclude possible confounding ophthalmological pathology: best-corrected visual acuity, intraocular pressure using noncontact tonometry (if intraocular pressure \( >20 \) mmHg, we used contact applanation tonometry), slit-lamp examination of the anterior and posterior segment, Heidelberg retinal tomography optic nerve head (ONH) analysis, and frequency doubling technology for visual fields. Tropicamide (0.5%) was administrated for pupil dilation to facilitate optimal ophthalmic examination. We followed the fourth European Glaucoma Guideline criteria: glaucoma was diagnosed when two of the three following measurements were abnormal: ocular pressure \( (>21 \) mmHg), structural glaucomatous changes (examined with Heidelberg retinal tomography using the Moorfields regression analysis), and functional changes (examined with frequency doubling technology) [28]. All examinations were interpreted by an experienced ophthalmologist (FDV). Exclusion criteria were ophthalmological conditions interfering with imaging or retinal vasculature, such as severe cataract, age-related macular degeneration, and glaucoma or systemic conditions such as diabetes mellitus.

2.6. Retinal vascular imaging

Retinal vasculature was measured by personnel blinded for diagnosis, using three imaging modalities: (1) fundus photography, (2) enhanced depth imaging OCT (EDI-OCT) and (3) OCT angiography (OCTA) (Fig. 1). Digital fundus images of 50° field of view of the macula and ONH were obtained using a Topcon TRC 50DX type IA (Topcon Medical Systems, Inc., Oakland, CA, USA). Macular photographs were assessed for incident pathology by an experienced ophthalmologist (FDV). Exclusion criteria were ophthalmological conditions interfering with imaging or retinal vasculature, such as severe cataract, age-related macular degeneration, and glaucoma or systemic conditions such as diabetes mellitus.

EDI-OCT scans were acquired with a Heidelberg Spectralis spectral domain-OCT, using the following protocol: central retina (macula) fast horizontal scanning; central 20° × 20° area; 25 B-scans (averaging 9 frames per b-scan); 512 a-scans per b-scan. Manual measurements of choroidal thickness were performed in five evenly distributed b-scans per macular volume scan (Supplementary Fig. 1) [14,16,17]. Five measurements per b-scan were performed: foveal, 1 mm nasal and temporal from the fovea and 2 mm nasal and temporal from the fovea. The anterior boundary of the choroid layer was defined as the hyperreflective band corresponding to the retinal pigment epithelium—Bruch’s membrane complex. To define the posterior boundary, each measurement point was categorized based on the presence or absence of the choroidal-scleral interface as a hyperreflective band, the suprachoroidal space as a hyporeflecting band, and/or a smooth line marking the posterior boundary on the OCT image. The posterior boundary was then defined as the outer limit of the choroidal-scleral interface, the inner limit of the suprachoroidal space, or the smooth line. If no clear boundary was identifiable over the length of the scan, the image was defined as ungradable. The averages of the measurements \( (n = 25) \) from both eyes were used for analysis of mean choroidal thickness.

OCTA was acquired using a Zeiss Model 5000 spectral domain-OCT with Angioplex and consisted of 6 \( × \) 6 mm scans of the macula, 350 b-scans each. Vascular density measured in the inner ring (Ø 1-3 mm around fovea) and outer ring (Ø 3-6 mm around fovea) of the Early Treatment in Diabetes Retinopathy Study grid. FAZ surface area was measured. Scans were visually assessed for quality. All scans had quality factors \( \geq 7/10 \) and could be considered “good” quality.
2.7. Statistical analysis

2.7.1. Power calculation

Based on a previous meta-analysis [12], comparing 374 AD cases compared to 707 control subjects, a decrease of 7.52 μm in CRAE can be expected. Assuming a true effect of 7.52 μm and a standard deviation of ≈15 μm, 28 subjects in each group are needed to reject the null hypothesis of no difference between the disease and control group with a power of 0.80. In addition, from the same meta-analysis a decrease of 10.74 μm in CRVE can be expected. Assuming a true effect of 10.74 μm and a standard deviation of ≈15 μm, 15 subjects in each group are needed to reject the null hypothesis of no difference between the disease and control group with a power of 0.80. From a previous report [16], a decrease of ≈60 μm in chorioidal thickness can be expected. Assuming a true effect of 60 μm and a standard deviation of ≈50 μm, 6 subjects in each group are needed to reject the null hypothesis of no difference between the disease and control group with a power of 0.80. We included ≥35 participants per disease group.

2.7.2. Data analysis

Data were visually tested for a normal distribution using histograms and Q-Q plots. Measures that were normally distributed were tested with an independent t-test, nonnormally distributed measures with a Mann-Whitney U test, and binary variables with a chi-squared test. Linear regression models were used to assess if changes in retinal vasculature (dependent) were attributable to diagnosis (independent) or age, sex, spherical equivalent, quality factor, and/or hypertension (covariates). All betas reported are standardized betas. spherical equivalent, quality factor, and/or hypertension attributable to diagnosis (independent) or age, sex, assess if changes in retinal vasculature (dependent) were

2.8. Data analysis

Data were visually tested for a normal distribution using histograms and Q-Q plots. Measures that were normally distributed were tested with an independent t-test, nonnormally distributed measures with a Mann-Whitney U test, and binary variables with a chi-squared test. Linear regression models were used to assess if changes in retinal vasculature (dependent) were attributable to diagnosis (independent) or age, sex, spherical equivalent, quality factor, and/or hypertension (covariates). All betas reported are standardized betas. spherical equivalent, quality factor, and/or hypertension attributable to diagnosis (independent) or age, sex, assess if changes in retinal vasculature (dependent) were

3. Results

Table 1 shows cohort characteristics. We included 50 AD patients and 38 control subjects from our retinal imaging [21] cohort with retinal vasculature imaging available. One AD case was excluded because of glaucoma. In addition, we excluded one AD case that was later found to have a programulin mutation, a mutation known to directly affect retinal integrity [33]. As a result, fundus photographs were available in 48 AD patients and 38 control participants. EDI-OCT and OCTA became available in the course of the study and were obtained in 41 AD patients and 31 control participants for EDI-OCT and 26 AD patients and 31 control participants for OCTA. AD cases were slightly older (65.4 y vs. 60.6 y, P < .01) and had MMSE and MRI atrophy scores indicative of an AD diagnosis. There was no difference between groups for WMH and lacunes indicating similar cerebrovascular loading. By design, all AD cases were amyloid positive and all control participants were amyloid negative based on CSF (n = 50), amyloid PET (n = 11),

Table 1

| Table 1 | Cohort characteristics | Alzheimer’s disease | Controls | P value |
|---------|------------------------|---------------------|----------|---------|
| Number  |                        | 48                  | 38       |         |
| Sex (m/f)|                       | 25/23               | 24/14    | .24*    |
| Age     |                        | 65.4 (±8.1)         | 60.6 (±5.0) | <.01  |
| MMSE    |                        | 23 (±3)             | 29 (±1)  | <.01    |
| Body mass index (kg/m²) |              | 24.4 (±3.1)         | 26.2 (±4.1) | .32*    |
| APOE e4/e4 genotype* | | 11 (23.4)          | 1 (2.9)   | <.01* |
| E4 homozygous, n (%) | | 22 (46.8)          | 9 (26.5)  | .05* |
| E4 negative, n (%) | | 14 (29.8)          | 24 (70.6) | <.01* |
| Blood pressure measures  |                         |                     |          |         |
| Systolic blood pressure (mmHg) | | 148.9 (±17.5) | 139.0 (±18.4) | .02 |
| Diastolic blood pressure (mmHg) | | 84.2 (±10.1) | 82.8 (±9.1) | .55 |
| Pulse pressure (mmHg) | | 64.7 (±12.6) | 56.2 (±12.5) | <.01 |
| Mean arterial pressure (mmHg) | | 84.4 (±64.1) | 59.3 (±83.5) | .01 |
| MRI† |                         |                     |          |         |
| Global cortical atrophy (GCA) | | 1 (0-2)         | 0 (0-1)   | <.01 |
| Medial temporal lobe atrophy (MTA) | | 1.5 (0-2.5) | 0 (0-2)   | <.01 |
| Parietal cortical atrophy (PCA) | | 1 (0-3)         | 0 (0-1)   | <.01 |
| Fazekas score | | 1 (0-3)         | 1 (0-2)   | .08 |
| Microbleeds (n) | | 0.1 (±0.4) | 2.7 (±14.6) | .35 |
| Lacunar infarcts (n) | | 0 (±0)         | 0.2 (±0.6) | .02 |
| CSF* |                        |                     |          |         |
| Aβ1-42 (ng/L) | | 555.1 (±106.2) | 1162.3 (±200.0) | <.01 |
| Tau-181 (ng/L) | | 715.1 (±304.5) | 242.2 (±85.7) | <.01 |
| pTau (ng/L) | | 89.0 (±28.3) | 43.0 (±11.8) | <.01 |
| Tau-181/Aβ1-42 ratio | | 1.3 (±0.5) | 0.2 (±0.1) | <.01 |
| Aβ PET** |                       |                     |          |         |
| Positive/negative | | 17/0           | 0/19      | <.01 |
| Ophthalmological |                         |                     |          |         |
| Intracranial pressure (mmHg) | | 16.3 (±2.3) | 16.0 (±2.1) | .39 |
| Visual acuity (LogMAR) | | 0.0 (±0.1) | −0.1 (0.1) | <.01 |

Significant associations (P < .05) are displayed in bold.

Abbreviations: APOE, apolipoprotein E; Aβ, amyloid beta; CSF, cerebrospinal fluid; MMSE, Mini-Mental State Examination; MRI, magnetic resonance imaging; PET, positron emission tomography.

*Chi-square test.
†Independent samples t-test.
‡Mann-Whitney U test.
§APOE e4/e4 genotype was available in 47 AD cases and 34 control subjects.
*MR1 was available in 47 AD cases and 35 control subjects.
**Amyloid PET was available in 17 AD cases and 19 control subjects.
or both (n = 25). As expected, APOE e4/e4 carriers were more prevalent in AD cases (70.2% vs. 29.4% in control subjects) [34]. Systolic blood pressure, pulse pressure, and mean arterial pressure were higher in control subjects (independent t-test, \( P = .02 \), \( P < .01 \), and \( P = .01 \), respectively).

### 3.1. Retinal vasculature parameters

#### 3.1.1. Singapore I Vessel analysis (SIVA)

Seven retinal vascular parameters, previously shown to have good reproducibility [32], showed no group differences between AD patients and control participants (Fig. 2A). Linear regression models assessing relationships between retinal vascular parameters and diagnosis, adjusted for age, and spherical equivalent (SE), showed no disease effect (Table 2). CRVE and FDa were found to be associated with age (β = −0.25, \( P = .03 \) and β = −0.28, \( P = .02 \), respectively) (Table 2). Adjusting analysis for systolic blood pressure, pulse pressure, or mean arterial pressure did not alter disease effects.

#### 3.1.2. Choroidal thickness analysis

Choroidal thickness in the macula showed no group differences between AD patients (246.4 μm, ±82.0) and control participants (251.3 μm, ±68.6) (independent t-test, \( P = .588 \)) (Fig. 2B). Linear regression models assessing relationships between choroidal thickness and diagnosis, adjusted for age, and SE showed no disease effect (β = 0.14, \( P = .24 \)) but was associated with age (β = −0.34, \( P = .01 \)) and SE (β = 0.43, \( P = .01 \)) (Table 2). Adjusting analysis for different measures of blood pressure did not alter AD disease effects.

#### 3.1.3. OCTA analysis

Vessel density in the inner and outer ring of the macula and the size of the FAZ showed no group differences between AD patients and control participants (Fig. 2C). Linear regression models assessing relationships between OCTA measures and diagnosis, adjusted for age, SE, and quality factor, showed no disease effect for vessel density in the inner ring (β = 0.02, \( P = .85 \)) or outer ring (β = −0.10, \( P = .36 \)), or FAZ (β = −0.14, \( P = .33 \)). Vessel density was, however, strongly associated with quality factor (inner ring [β = 0.77, \( P < .001 \)], outer ring [β = 0.65, \( P < .001 \)]), unlike Fazekas (β = −0.04, \( P = .81 \)) (Table 2). Adjusting analysis for different measures of blood pressure did not alter AD disease effects.

#### 3.2. Relationships between retinal vascular parameters and white matter hyperintensities

To assess relationships between retinal vasculature and intracerebral vascular changes, we correlated retinal vascular parameters with WMH scores on MRI (Fazekas score), adjusting for age and sex. Vessel density in the outer ring was found to be inversely associated with Fazekas score in AD participants (β = −0.64, \( P < .01 \)), while curvature tortuosity of veins was inversely associated with Fazekas score in control subjects (β = −0.56, \( P < .01 \)). No associations were found between other retinal vascular parameters and WMH scores (Table 3).

#### 3.3. Relationships between retinal vascular parameters and MMSE, CSF Aβ1-42, and APOE e4/e4 genotype

Both adjusted and unadjusted for age and sex, no relationships between retinal vascular parameters and MMSE or CSF Aβ1-42 were observed. Comparing APOE e4/e4 carriers (n = 44) versus noncarriers (n = 37), irrespective of diagnosis, no differences in retinal vascular measures were found (independent samples t-test, all \( P > .16 \)).

#### 3.4. Stratified analyses for early- versus late-onset Alzheimer’s disease

Stratifying analyses of retinal vascular parameters, choroidal thickness, and OCTA measures for early- versus late-onset AD showed no group differences between the two disease group and controls, or between disease groups.

### 4. Discussion

In this cross-sectional study using three imaging modalities, we found that there were no group differences in retinal vasculature between well-phenotyped, amyloid confirmed, AD and control cases after correction for age and sex. Stratifying cases for early- versus late-onset AD yielded similar results. Vessel density in the outer ring of the macula was found to be associated with WMH scores on MRI in AD participants, while curvature tortuosity of veins was associated with WMH scores in control subjects.

Our findings of unaltered retinal vascular caliber parameters on fundus photography in AD confirm a recent study that included biomarker confirmed AD cases (n = 29) based on amyloid PET imaging [13]. In that same study, decreased FDa was observed in subcortical VCI patients [13]. In contrast, other studies found differences in various retinal vascular parameters in different directions, that include decreased CRVE [35,36], CRAE [36], fractal dimension of the venular network [35–37], FDa [35], cTORTa [37] and increased cTORTa [35], and curvature tortuosity of the venules [35] in AD patients compared to control participants. As these cohorts were larger (n > 100 per patient group), it might indicate that the effect size of retinal vascular parameters is small and possibly remained undetected in our study. Alternatively, as previous studies used clinical diagnosis, cohorts could have consisted of dementia cases with a primarily vascular etiology or of cases with relevant vascular copathology. In those cases, retinal (micro)vasculature changes may...
In this study, describing OCTA measurements in amyloid-positive AD cases for the first time, we found no differences in vessel density and FAZ, while a strong effect of quality factor (QF) on vessel density measurements was observed \( [\beta > 0.65, P < .001] \) in scans with acceptable QFs (between 7 and 10). In contrast, previous studies described a decrease in vessel density and an increase in FAZ surface area in (preclinical) AD cases \([18–20]\). However, as ophthalmological confounders, age, SE, and QF were not always taken into account, findings of those studies may represent an overestimation of true disease effects.

Given the thorough characterization of our participants, we were able to correlate retinal vascular measurements with WMH on MRI, \( A_\beta^{[1-42]} \), Tau, \( \tau \), and pTau in CSF and MMSE. Venular tortuosity was inversely correlated with WMH scores on MRI in control subjects, while in contrast an earlier study reported a positive correlation between WMH and venular tortuosity in control subjects \([32]\). Confirming an earlier report, we found an inverse association between macular vessel density and WMH scores in AD, possibly reflecting microvascular changes in chronic cerebral microinfarction. Similarly, in a recent report, a relation between WMH volume and fractal dimension was observed \([13]\). These findings need confirmation in larger cohorts, including volumetric...
measures of WMHs. We found no associations between retinal vascular parameters and CSF biomarkers or MMSE.

A limitation of our study is its relatively small sample size and incomplete collection of all vascular markers, hampering sensitivity for small diseases effects on retinal vasculature. However, despite its relevance for understanding involvement of retinal vasculature in AD pathophysiology, the added value of these small effects for clinical use as a biomarker remain doubtful. As our cohort consisted of cases with relatively little vascular comorbidity, studies in VCI and mixed pathology are warranted to assess the use of retinal vascular parameters to detect vascular (co)-pathology in these populations.

5. Conclusion

Using a multimodal retinal imaging approach in well-characterized amyloid status–confirmed AD and control cases, we found no evidence that retinal vasculature can be used as a noninvasive biomarker for AD.

Acknowledgments

The authors would like to thank all patients, control subjects, and their families for their contributions to our study and Heidelberg and Zeiss for providing their systems for the eye imaging. This study was designed and conducted according to the Declaration of Helsinki, and the study protocol was approved by the Ethical Committee of the Amsterdam UMC, location VUmc. All participants gave their written informed consent for participation in this study in the presence of their caregiver. Research of the Alzheimer Center Amsterdam is part of the neurodegeneration research program of Amsterdam Neuroscience. The Alzheimer Center Amsterdam is supported by Stichting Alzheimer Nederland and Stichting VUmc fonds. The clinical database structure was developed with funding from Stichting Dioraphte. FB is supported by the NIHR biomedical research center at UCL. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Supplementary Data

Supplementary data related to this article can be found at https://doi.org/10.1016/j.dadm.2019.03.006.

RESEARCH IN CONTEXT

1. Systematic Review: The authors searched PubMed for all publications assessing retinal microvasculature in Alzheimer’s disease (AD). Well-phenotyped cohorts including amyloid status, white matter hyperintensities on magnetic resonance imaging and ophthalmological screening have not previously been examined.

2. Interpretation: In this study, representing the largest cohort with amyloid proven AD cases, we show that retinal vasculature does not discriminate AD from control participants, despite evident changes on clinical, neuroimaging, and cerebrospinal fluid measures, querying the use of retinal vasculature measurements as AD biomarker.

3. Future directions: Future studies in cases with vascular cognitive impairment and mixed pathology are needed to assess the role of retinal vasculature as noninvasive biomarker for vascular (co)-pathology.

References

[1] Scheltens P, Blennow K, Breteler MMB, de Strooper B, Frisoni GB, Salloway S, et al. Alzheimer’s disease. Lancet 2016.
